Evidence map›Paper›PMID 35818846›Full record

ArticleBiotechnology progress2022

Design and optimization of membrane chromatography for monoclonal antibody charge variant separation.

Sathish Nadar, Balaji Somasundaram, Marcela Charry, Jagan Billakanti, Evan Shave, Kym Baker, Linda H L Lua

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology progress, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Antibody Aggregate Removal by Multimodal Chromatography.Molecules (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Sathish NadarAustralian Research Council Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.
Balaji SomasundaramProtein Expression Facility, The University of Queensland, Brisbane, Australia.ORCID 0000-0002-4555-2605
Marcela CharryProtein Expression Facility, The University of Queensland, Brisbane, Australia.
Jagan BillakantiCytiva, Global Life Sciences Solutions Australia Pty Ltd, Sydney, Australia.
Evan ShaveAustralian Research Council Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.
Kym BakerPatheon Biologics, Pharma Services Group, Thermo Fisher Scientific, Brisbane, Australia.
Linda H L LuaAustralian Research Council Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.
Australian Research Council · AUThe University of Queensland · AUServices Australia · AUThermo Fisher Scientific (Israel) · IL

Funding

Australian Research Council Training Centre for Biopharmaceutical Innovation IC160100027
6 · The paper itself

Abstract

The manufacturing scale implementation of membrane chromatography to purify monoclonal antibodies has gradually increased with the shift in industry focus toward flexible manufacturing and disposable technologies. Membrane chromatography are used to remove process-related impurities such as host cell proteins (HCPs) and DNA, leachates, and endotoxins, with improved productivity and process flexibility. However, application of membrane chromatography to separate product-related variants such as charge variants has not gained major traction due to low-binding capacity. The work reported here demonstrates that a holistic process development strategy to optimize static binding (pH and salt concentration) and dynamic process (membrane loading, flowrate, and gradient length) parameters can alleviate the capacity limitations. The study employed high throughput screening tools and scale-down membranes for intermediate and polishing purification of the model monoclonal antibody. An optimized process consisting of anion exchange and cation exchange membrane chromatography reduced the acidic variants present in Protein A eluate from 89.5% to 19.2% with 71% recovery of the target protein. The membrane chromatography process also cleared HCP to below limit of detection with 6- to 30-fold higher membrane loading, compared to earlier reported values. The results confirm that membrane chromatography is effective in separating closely related product variants when supported by a well-defined process development strategy.

Indexed as

Antibodies, MonoclonalSodium ChlorideAnionsCationsChromatography, Ion ExchangeAnionsAntibodies, MonoclonalCationsSodium Chloridecharge variantsdownstream processinghigh throughput process developmentmembrane chromatographymonoclonal antibody

Identifiers

PMID35818846
PMCPMC10078440
OpenAlexW4285077033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.